JPRN-UMIN000002515
Recruiting
未知
Multicenter clinical study evaluating safety and efficacy of iron chelation therapy in patients with transfusion-induced iron overload - Multicenter clinical study evaluating safety and efficacy of iron chelation therapy in patients with transfusion-induced iron overload
The National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan0 sites100 target enrollmentSeptember 24, 2009
ConditionsTransfusion-induced iron overload
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Transfusion-induced iron overload
- Sponsor
- The National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with severe renal or hepatic dysfunction. Patients who are pregnant or breastfeeding or expecting pregnancy. Patients with history of hypersensitivity to deferasirox. Patients who have been judged as inappropriate for any reasons by the concerning investigators.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
WS-01 Investigator-initiated clinical trialJPRN-jRCT1092220031obuyuki Sakai, Kobe City Hospital Organization Kobe City Medical Center General Hospital20
Completed
Phase 3
WS-01 long-term observational studyJPRN-jRCT1090220035Kobe City Hospital Organization General HospitalNobuyuki Sakai20
Active, not recruiting
Phase 1
A multicentre study to assess the safety and efficacy of sodium hyaluronate (Hyalgan-F) produced by fermentation in knee psteoarthritis.Knee oasteoarthritisEUCTR2005-002735-27-LVFidia Farmaceutici SpA120
Completed
Phase 3
A Study to Evaluate Efficacy of DDX-01 which Supports Screening for Diabetic Retinopathy and Diabetic Macular EdemaDiabetisJPRN-jRCT2032220358Tomita Koji275
Completed
Not Applicable
Multicenter Clinical Study Evaluating the Safety and Efficacy of Dasatinib Treatment and its Discontinuation in Patients with Chronic Phase Chronic Myelogenous Leukemia who had Reached Complete Molecular Response during Imatinib TherapyChronic Phase Chronic Myelogenous LeukemiaJPRN-UMIN000007221Juntendo University School of Medicine40